

# SPECIAL 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

# I Background Information:

### A 510(k) Number

K200033

## **B** Applicant

Instrumentation Laboratory Co.

## **C** Proprietary and Established Names

HemosIL von Willebrand Factor Antigen

#### **D** Regulatory Information

Product Code(s)	Classification	Regulation Section	Panel
GGP	Class II	21 CFR 864.7290 - Factor Deficiency Test	HE - Hematology

#### **II** Review Summary:

This 510(k) submission contains information/data on modifications made to the submitter's own CLASS II, device requiring 510(k). The following items are present and acceptable.

- 1. The name and 510(k) number of the SUBMITTER'S previously cleared device (HemosIL von Willebrand Factor Antigen, K992704).
- 2. Submitter's statement that the **INDICATIONS FOR USE/INTENDED USE** of the modified device as described in its labeling **HAS NOT CHANGED** along with the proposed labeling which includes instructions for use, package labeling, and if available, advertisements or promotional materials.
- 3. A description of the device **MODIFICATION(S)**, including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the **FUNDAMENTAL SCIENTIFIC TECHNOLOGY** of the modified device **has not changed**.

The change was for a modified Rheumatoid Factor (RF) interference claim in the "Limitations/Interfering substances" section of the HemosIL von Willebrand Factor Antigen package insert from "the presence of Rheumatoid Factor may produce an overestimation of vWF:Ag results on ACL Family Systems" and "vWF:Ag results on ACL TOP Family and ACL TOP Family 50 Series are not affected by Rheumatoid Factor up to 750 IU/mL" to a new claim. The new claim states "vWF:Ag results on ACL Family Systems are not affected by Rheumatoid Factor up to 50 IU/mL" and "vWF:Ag results on ACL TOP Family and ACL TOP Family and ACL TOP Family Systems are not affected by Rheumatoid Factor up to 50 IU/mL" and "vWF:Ag results on ACL TOP Family and ACL TOP Family 50 Series are not affected by Rheumatoid Factor up to 50 IU/mL" and "vWF:Ag results on ACL TOP Family and ACL TOP Family 50 Series are not affected by Rheumatoid Factor up to 50 IU/mL" and "vWF:Ag results on ACL TOP Family and ACL TOP Family 50 Series are not affected by Rheumatoid Factor up to 50 IU/mL" and "vWF:Ag results on ACL TOP Family and ACL TOP Family 50 Series are not affected by Rheumatoid Factor up to 50 IU/mL" and "vWF:Ag results on ACL TOP Family and ACL TOP Family 50 Series are not affected by Rheumatoid Factor up to 50 IU/mL"

- 4. Comparison Information (i.e., similarities and differences) to the submitter's legally marketed predicate device including, labeling, intended use, and physical characteristics.
- 5. A Design Control Activities Summary which includes:
  - a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis.
  - b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied.